Der Pneumologe

, Volume 8, Issue 1, pp 25–31

Resistente Tuberkulose

Zunehmende Probleme und Lösungsansätze
Leitthema

Zusammenfassung

Die Medikamentenresistenz stellt bei der Tuberkulose (TB) ein zunehmendes Problem dar. Eine multiresistente (MDR-)TB wird bereits bei 440.000 Fällen, eine extensiv resistente (XDR-)TB bei 25.000 Fällen der weltweit über 9 Mio. jährlichen Neuerkrankungen angenommen. Um diese dramatische Entwicklung in den Griff zu bekommen, sind international konzertierte Anstrengungen notwendig, die sowohl die Therapie auf der Basis von Resistenztestungen als auch strikte Infektionsverhütungsmaßnahmen beinhalten müssen. Es mangelt jedoch an Laborkapazitäten, gerade in den am meisten betroffenen Ländern (China, Indien, frühere Sowjetunion), aber auch an ausreichend wirksamen Medikamenten, insbesondere bei der XDR-TB.

Schüsselwörter

Tuberkulose Medikamentenresistenz Epidemiologie HIV-Infektion Fallmanagement 

Drug-resistant tuberculosis

Growing problems and solutions

Abstract

Drug resistance is an increasing problem in the treatment of tuberculosis (TB). Multidrug-resistant (MDR-)TB is already assumed to be present in 440,000, extensively resistant (XDR-)TB in 25,000 of the nine million new TB cases worldwide per year. To gain control of this dramatic development, internationally concerted efforts are needed regarding both treatment regimens based on drug resistance tests and strict infection prevention measures. However, particularly the most affected countries (China, India, and the former Soviet Union) lack laboratory capacities, but also effective drugs, especially for XDR-TB.

Keywords

Tuberculosis Drug resistance Epidemiology HIV infection Case management 

Literatur

  1. 1.
    Aerts A, Hauer B, Wanlin M et al (2006) Tuberculosis and tuberculosis control in European prisons. Int J Tuberc Lung Dis 11:1213–1223Google Scholar
  2. 2.
    Blaas SH, Mütterlein R, Weig J et al (2008) Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 8:60CrossRefPubMedGoogle Scholar
  3. 3.
    Boehme CC, Nabeta P, Hillemann D (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015CrossRefPubMedGoogle Scholar
  4. 4.
    Bone A, Aerts A, Grzemska M et al (2001) TB control in prisons. A manual for programme managers. WHO/CDS/TB/2000.281Google Scholar
  5. 5.
    Caminero JA (2008) Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 12:869–877PubMedGoogle Scholar
  6. 6.
    Caminero JA, Sotgin G, Zumla A et al (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10:621–629CrossRefPubMedGoogle Scholar
  7. 7.
    Castell S, Hauer B, Brodhun B, Haas W (2010) Epidemiologie der Tuberkulose. Aktuelle Situation in Deutschland und weltweit. Pneumologe [Epub ahead of print]Google Scholar
  8. 8.
    Chiang C-Y, Yew WW (2009) Multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 13:304–311PubMedGoogle Scholar
  9. 9.
    Cohen T, Colijn C, Wright A et al (2008) Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med 177:1302–1306CrossRefPubMedGoogle Scholar
  10. 10.
    Davies PDO (2003) The world wide increase in tuberculosis: how demographic change, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 35:235–243CrossRefPubMedGoogle Scholar
  11. 11.
    Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (2001) Richtlinien zur medikamentösen Behandlung der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie 33:494–511Google Scholar
  12. 12.
    Dietze R, Hadad JD, McGee B et al (2008) Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178:1180–1185CrossRefPubMedGoogle Scholar
  13. 13.
    Eker B, Orzmann J, Migliori GB et al (2008) Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 14:1700–1706CrossRefPubMedGoogle Scholar
  14. 14.
    Faustini A, Hall AJ, Perruci CA (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61:158–163CrossRefPubMedGoogle Scholar
  15. 15.
    Floyd K, Pantoja A (2008) Financial resources required for tuberculosis control to achieve global targets set for 2015. Bull World Health Organ 86:568–576CrossRefPubMedGoogle Scholar
  16. 16.
    Forßbohm M, Loddenkemper R, Rieder HL (2003) Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis 7:973–979PubMedGoogle Scholar
  17. 17.
    Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:231–279Google Scholar
  18. 18.
    French CE, Glynn JR, Kruijshaar ME et al (2008) The association between HIV and antituberculosis drug resistance. Eur Respir J 32:718–725CrossRefPubMedGoogle Scholar
  19. 19.
    Frieden TR, Sterling T, Pablos-Mendez A et al (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521–526CrossRefPubMedGoogle Scholar
  20. 20.
    Gandhi NR, Moll A, Sturm AW (2006) Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575–1580CrossRefPubMedGoogle Scholar
  21. 21.
    Gandhi NR, Shah NS, Andrews JR (2010) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181:80–86CrossRefPubMedGoogle Scholar
  22. 22.
    Glynn JR, Kremer K, Borgdorff MW et al (2006) Beijing/W genotype Mycobacterium tuberculosis and drug resistance. European concerted action on new generation genetic markers and techniques for the epidemiology and control of tuberculosis. Emerg Infect Dis 12:736–743Google Scholar
  23. 23.
    Gupta R, Cegielski JP, Espinal MA et al (2002) Increasing transparency in partnerships for health – introducing the Green Light Committee. Trop Med Int Health 7:970–976CrossRefPubMedGoogle Scholar
  24. 24.
    Hauer B, Kunitz F, Sagebiel D et al (2007) Übersicht zur DZK-Studie „Untersuchungen zur Tuberkulose in Deutschland: Molekulare Epidemiologie, Resistenzsituation und Behandlung“. In: Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (Hrsg). 30. Informationsbericht, Berlin, S 74–84Google Scholar
  25. 25.
    Iseman MD (2002) Tuberculosis therapy: past, present and future. Eur Respir J 20(Suppl 36):87s–94sCrossRefGoogle Scholar
  26. 26.
    Kang MW, Kim HK, Choi YS (2010) Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis. Ann Thorac Surg 89:1597–1602CrossRefPubMedGoogle Scholar
  27. 27.
    Keshavjee S, Gelmanova I, Farmer PE et al (2008) Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372:1403–1409CrossRefPubMedGoogle Scholar
  28. 28.
    Kim DH, Kim HJ, Part S-K et al (2008) Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 178:1075–1082CrossRefPubMedGoogle Scholar
  29. 29.
    Kliiman K, Altraja A (2009) Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 33:1085–1094CrossRefPubMedGoogle Scholar
  30. 30.
    Kwon YS, Kim YH, Suh GY et al (2008) Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 47:496–502CrossRefPubMedGoogle Scholar
  31. 31.
    Lange C, Grobusch MP, Wagner D (2008) Extensiv-resistente Tuberkulose (XDR-TB). Dtsch Med Wochenschr 133:374–376CrossRefPubMedGoogle Scholar
  32. 32.
    Laserson KF, Thorpe LE, Leimane V et al (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9:640–645PubMedGoogle Scholar
  33. 33.
    Leung CC, Rieder HL, Lange C, Yew WW (2010) Treatment of latent infection with M. tuberculosis: update 2010. Eur Respir J (Epub ahead of print, doi:10.1183/09031936.00079310)Google Scholar
  34. 34.
    Loddenkemper R, Sagebiel D, Brendel A (2002) Strategies against multidrug-resistant tuberculosis. Eur Respir J 20(Suppl 36):66–77CrossRefGoogle Scholar
  35. 35.
    Loddenkemper R, Hauer B (2010) Resistente Tuberkulose. Große Herausforderung durch eine Weltepidemie. Dtsch Arztebl Int 107:10–19PubMedGoogle Scholar
  36. 36.
    Migliori GB, Besozzi G, Girardi E et al (2007) Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 30:623–626CrossRefPubMedGoogle Scholar
  37. 37.
    Migliori GB, Loddenkemper R, Blasi F et al (2007) 125 years after Robert Koch’s discovery of the tubercle bacillus. Is ‚science‘ enough to tackle the epidemic? Eur Respir J 29:423–427CrossRefPubMedGoogle Scholar
  38. 38.
    Mitchison DA (1965) Chemotherapy of tuberculosis: a bacteriologist’s viewpoint. Br Med J 1:1333–1340CrossRefPubMedGoogle Scholar
  39. 39.
    Mitnick CD, Shin SS, Seung KJ et al (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359:563–574CrossRefPubMedGoogle Scholar
  40. 40.
    Monedero I, Caminero JA (2010) Management of multidrug-resistant tuberculosis: an update. Ther Adv Respir Dis 4:117–127CrossRefPubMedGoogle Scholar
  41. 41.
    Nachega JB, Chaisson RE (2003) Tuberculosis drug resistance: a global threat. Clin Infect Dis 36(Suppl 1):S24–S30CrossRefPubMedGoogle Scholar
  42. 42.
    Nathanson E, Nunn P, Uplekar M et al (2010) MDR tuberculosis – critical steps for prevention and control. N Engl J Med 363:1050–1058CrossRefPubMedGoogle Scholar
  43. 43.
    Nunn P, Reid A, De Cock KM (2007) Tuberculosis and HIV infection: the global setting. J Infect Dis 196:5–14CrossRefGoogle Scholar
  44. 44.
    Pai M, O’Brien R (2008) New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 29:560–568CrossRefPubMedGoogle Scholar
  45. 45.
    Parnish N, Carrol K (2008) Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis. Future Microbiol 3:405–413CrossRefGoogle Scholar
  46. 46.
    Punga VV, Jakubowiak WM, Danilova ID et al (2009) Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis 13:1309–1312PubMedGoogle Scholar
  47. 47.
    Rajbhandary SS, Marks SM, Bock NN (2004) Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 8:1012–1016PubMedGoogle Scholar
  48. 48.
    Raviglione MC, Uplekar MW (2006) WHO’s new Stop TB Strategy. Lancet 367:952–955CrossRefPubMedGoogle Scholar
  49. 49.
    Richter E, Rüsch-Gerdes S, Hillemann D (2009) Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Resp Med 3:497–510CrossRefGoogle Scholar
  50. 50.
    Robert Koch-Institut (2010) Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2008. Robert Koch-Institut, Berlin. http://www.rki.deGoogle Scholar
  51. 51.
    Rüsch-Gerdes S, Hillemann D (2008) Moderne mykobakteriologische Labordiagnostik. Pneumologie 62:533–540CrossRefPubMedGoogle Scholar
  52. 52.
    Scholten JN, Vlas SJ de, Zaleskis R (2008) Under-reporting of HIV infection among cohorts of TB patients in the new WHO European Region, 2003–2004. Int J Tuberc Lung Dis 12:85–91PubMedGoogle Scholar
  53. 53.
    Schwalbe N, Harrington P (2002) HIV and tuberculosis in the former Soviet Union. Lancet 360:19–20CrossRefGoogle Scholar
  54. 54.
    Shah NS, Pratt R, Armstrong L (2008) Extensively drug-resistant tuberculosis in the United States, 1993–2007. JAMA 300:2153–2160CrossRefPubMedGoogle Scholar
  55. 55.
    Small PM, Pai M (2010) Tuberculosis diagnosis – time for a game change. (Editorial) N Engl J Med 363:1070–1071Google Scholar
  56. 56.
    Sotgiu G, Ferrara G, Matteelli A et al (2009) Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 33:871–881CrossRefPubMedGoogle Scholar
  57. 57.
    Vareldzis BP, Grosset J, Kantor IN de et al (1994) Drug-resistant tuberculosis, laboratory issues. WHO recommendations. Int J Tuberc Lung Dis 75:1–7CrossRefGoogle Scholar
  58. 58.
    Van Deun A, Maug AK, Salim MA (2010) Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 182:684–692Google Scholar
  59. 59.
    Velayati AA, Masjedi MR, Farnia P et al (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli. Chest 136:420–425CrossRefPubMedGoogle Scholar
  60. 60.
    World Health Organization (2000) Guidelines for establishing DOTS-Plus projects for the management of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, WHO/CDS/TB/2000.278. Geneva, SwitzerlandGoogle Scholar
  61. 61.
    WHO Regional Office for Europe (2007) Status paper on prisons and tuberculosis. WHO, Kopenhagen, Dänemark. EUR/07/5063912Google Scholar
  62. 62.
    World Health Organization (2008) Anti-tuberculosis drug resistance in the world. Report No. 4. WHO/HTM/TB/2008:394Google Scholar
  63. 63.
    World Health Organization (2010) Multidrug- and extensively drug-resistant TB (M/XDR-TB). 2010 Global report on surveillance and response. WHO, Geneva, Switzerland. WHO/HTM/TB/2010.3Google Scholar
  64. 64.
    World Health Organization (2008) The Stop TB Strategy. Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. World Health Organization, Geneva, WHO/HTM/STB/2008Google Scholar
  65. 65.
    World Health Organization (2009) Global tuberculosis control. A short update to the 2009 report. WHO, Geneva, Switzerland, WHO/HTM/TB/2009.426Google Scholar
  66. 66.
    World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008:402Google Scholar
  67. 67.
    World Health Organization (2009) Global tuberculosis control: epidemiology, strategy, financing. WHO, Geneva, Switzerland, WHO/HTM/TB2009.411Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Abteilung für InfektionsepidemiologieRobert-Koch-InstitutBerlinDeutschland
  2. 2.Deutsches Zentralkomitee zur Bekämpfung der TuberkuloseBerlinDeutschland

Personalised recommendations